Page 392 - Read Online

Gironés et al. Age-related efficacy of treatment in metastatic NSCLC

Table 2: Treatment date and comparison between age
Elderly EGFR mutated groups
Men never smoker Women never smoker Men smoker Men exsmoker Young Elders P
(162)
(160)
8% Treatment
12% Yes 139 (86%) 102 (63%)
40% No 23 (14%) 57 (37%) P = 0.0001
Treatment and PS P = 0.52
PS 0-1 136 98
Yes 136 (100%) 95 (97%)
No 0 3 (3%)
PS 2 26 61
40% Yes 3 (12%) 7 (11%)
No 23 (88%) 54 (89%)
Kind of treatment and PS
PS 0-1 136 95
Chemotherapy 118 (86%) 71 (74%)
Figure 1: EGFR mutation and smoking habit in elderly patients. Radiotherapy 6 (4%) 8 (8%)
EGFR: epidermal growth factor receptor EGFR-TKI 12 (10%) 16 (18%) P = 0.0001
PS 2 3 7
palliative brain radiation in the two groups (3 and 6; EGFR-TKI 0 3 (100%) 1 (15%)
6 (85%)
Radiotherapy
10%). Elderly patients received less chemotherapy (P Kind of chemotherapy 118 71 P = 0.035
= 0.0001) and were more likely to receive palliative Cisplatin-combination 48 (41%) 4 (5%)
radiation as sole treatment (81% vs. 5%). In the Carboplatin-combination 41 (34%) 42 (60%)
21 (30%)
8 (7%)
Monotherapy
younger group, of the 124 patients with PS 0-1 suitable Bevacizumab combination 21 (18%) 2 (2%)
for chemotherapy (excluding 12 patients with EGFR EGFR: epidermal growth factor receptor; TKI: tyrosine kinase
mutation); 118 (95%) were treated with chemotherapy. inhibitor; PS: performance status
In the elderly group, 71 of 98 patients (72%) suitable For the global series, overall survival was 8.979 months
for chemotherapy received this treatment. More elderly [95% confidence interval (CI) 7.949-10.08] and there
patients with good PS received palliative radiotherapy was no difference between age groups (9.42 vs. 8.48
as sole treatment (4% vs. 8%, P = 0.0001). Overall, of
the 189 patients that received chemotherapy (58.6% months; P = 0.0238) [Figure 2].
of the global series), 62.5% were in the younger group
vs. 37.5% who were elderly (P = 0.0001). In terms of According to the univariate analysis using Cox
chemotherapy, the elderly received more carboplatin proportional hazard regression analysis, the following
combinations (34% vs. 60%), monotherapy (6% vs. factors were related to better survival: female gender,
30%) and were less likely to receive bevacizumab ECOG PS 0-1, adenocarcinoma histology, no history of
combinations (2% vs. 18%) (P = 0.035). All patients smoking, presence of EGFR mutation, administration
with EGFR mutation received first line EGFR TKI. Only of treatment, chemotherapy and EGFR-TKI therapy.
one patient with an EGFR mutation in the elderly group
had PS 2.

Overall survival
AGE = ＞ 70
1.0
No
Yes
No-censored
0.8 Yes-censored
0.6

0.4

0.2

0.0
0 10 20 30 40 50 Figure 3: Comparison: treated versus untreated young patients.
Survival in months EGFR: epidermal growth factor receptor; TKI: tyrosine kinase
Figure 2: Comparison on overall survival between age groups inhibitor; PS: performance status
382 Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ September 30, 2016